IQV vs. MRNA: IQVIA vs. Moderna Stock Comparison

Company Profile

IQVIA (IQV) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while MRNA is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IQVIA (IQV) reports 21.39%, ranking against industry peers normally.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile IQVIA (IQV) reports 8.05%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile IQVIA (IQV) reports 13.73%, ranking against industry peers normally.

Profitability Metrics

Growth

IQVIA (IQV) at 5.87% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: IQVIA (IQV) reports EPS growth of 4.67%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both IQVIA (IQV) at 0.83 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Moderna (MRNA) at 0.19 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither IQVIA (IQV) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither IQVIA (IQV) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: IQVIA (IQV) trades at 33.07 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

IQVIA (IQV) at 2.59 looks cheap on sales in the lower P/S ratio quartile, while Moderna (MRNA) at 45.55 looks rich in the upper quartile — a clear gap in price per dollar of revenue.

Both IQVIA (IQV) at 6.73 and Moderna (MRNA) at 11.58 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics